{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:19:19Z","timestamp":1791202759149,"version":"4.2.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T00:00:00Z","timestamp":1441584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11255-015-1100-3","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T05:08:25Z","timestamp":1441602505000},"page":"1619-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Patient preferences for treating refractory overactive bladder in the UK"],"prefix":"10.1007","volume":"47","author":[{"given":"Hashim","family":"Hashim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F. P.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlan","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,7]]},"reference":[{"key":"1100_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"B Haylen","year":"2010","unstructured":"Haylen B, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5\u201326","journal-title":"Int Urogynecol J"},{"issue":"3","key":"1100_CR2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.juro.2010.10.048","volume":"185","author":"CL Link","year":"2011","unstructured":"Link CL, Steers WD, Kusek JW, McKinlay JB (2011) The Association of Adiposity and Overactive Bladder appears to differ by gender: results from the Boston Area Community Health (BACH) Survey. J Urol 185(3):955\u2013963","journal-title":"J Urol"},{"issue":"7","key":"1100_CR3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108(7):1132\u20131138","journal-title":"BJU Int"},{"issue":"6","key":"1100_CR4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306\u20131314","journal-title":"Eur Urol"},{"issue":"2","key":"1100_CR5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.urology.2012.09.028","volume":"81","author":"UJ Lee","year":"2013","unstructured":"Lee UJ, Scott VC, Rashid R et al (2013) Defining and managing overactive bladder: disagreement among the experts. Urology 81(2):257\u2013262","journal-title":"Urology"},{"issue":"14","key":"1100_CR6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/14656566.2013.823158","volume":"14","author":"DS Elterman","year":"2013","unstructured":"Elterman DS, Chughtai B, Kaplan SA, Barkin J (2013) Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother 14(14):1987\u20131991","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1100_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00192-011-1655-1","volume":"23","author":"L Brubaker","year":"2012","unstructured":"Brubaker L, Gousse A, Sand P et al (2012) Treatment satisfaction and goal attainment with onabotulinumtoxin A in patients with incontinence due to idiopathic OAB. Int Urogynecol J 23(8):1017\u20131025","journal-title":"Int Urogynecol J"},{"issue":"1","key":"1100_CR8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2005.01.036","volume":"66","author":"H Schulte- Baukloh","year":"2005","unstructured":"Schulte- Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66(1):82\u201387","journal-title":"Urology"},{"issue":"2","key":"1100_CR9","first-page":"180","volume":"33","author":"M Levy","year":"2014","unstructured":"Levy M et al (2014) Patient defined goals of care in treatment of medication refractory overactive bladder. Neurourol Urodyn 33(2):180","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1100_CR10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.juro.2010.09.090","volume":"185","author":"RK Leong","year":"2011","unstructured":"Leong RK, Marcelissen TA, Nieman FH, De Bie RA, Van Kerrebroeck PE, De Wachter SG (2011) Satisfaction and patient experience with sacral neuromodulation: results from a single center sample survey. J Urol 185(2):588\u2013592","journal-title":"J Urol"},{"issue":"1","key":"1100_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000316080","volume":"86","author":"RM Bauer","year":"2011","unstructured":"Bauer RM et al (2011) Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome. Urol Int 86(1):68\u201372","journal-title":"Urol Int"},{"issue":"4","key":"1100_CR12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.aju.2013.07.003","volume":"11","author":"AS El-Azab","year":"2013","unstructured":"El-Azab AS, Moeen AM (2013) The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty. Arab J Urol 11(4):344\u2013349","journal-title":"Arab J Urol"},{"issue":"2","key":"1100_CR13","first-page":"266","volume":"30","author":"H Imam","year":"2011","unstructured":"Imam H (2011) Patient satisfaction after intravesical botulinum toxin type a injection for refractory detrusor overactivity. Neurourol Urodyn 30(2):266","journal-title":"Neurourol Urodyn"},{"key":"1100_CR14","unstructured":"Urinary incontinence in women: the management of urinary incontinence in women [Internet], 2nd ed. The Royal College of Obstetricians and Gynaecologists, London 2013 http:\/\/www.nice.org.uk\/guidance\/cg171\/resources\/cg171-urinary-incontinence-in-women-full-guideline3"},{"issue":"8","key":"1100_CR15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00192-014-2360-7","volume":"25","author":"P Balchandra","year":"2014","unstructured":"Balchandra P, Rogerson L (2014) Women\u2019s perspective: intra-detrusor Botox\u00ae versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 25(8):1059\u20131064","journal-title":"Int Urogynecol J"},{"issue":"Suppl. 7","key":"1100_CR16","first-page":"45","volume":"109","author":"I Rudd","year":"2012","unstructured":"Rudd I, Kavia R, Jenks J et al (2012) Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity (IDO) [Abstract]. BJU Int 109(Suppl. 7):45","journal-title":"BJU Int"},{"issue":"3","key":"1100_CR17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/erp.10.29","volume":"10","author":"TN Flynn","year":"2010","unstructured":"Flynn TN (2010) Valuing citizen and patient preferences in health: recent developments in three types of best\u2013worst scaling. Expert Rev Pharmacoecon Outcomes Res 10(3):259\u2013267","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1100_CR18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11589190-000000000-00000","volume":"4","author":"J Bridges","year":"2011","unstructured":"Bridges J, Kinter E, Schmeding A et al (2011) Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks. Patient 4:267\u2013275","journal-title":"Patient"},{"key":"1100_CR19","unstructured":"Umberger W, Stringer R, Mueller SC (2010) Selected paper prepared for presentation at the agricultural & applied economics. Using Best\u2013Worst Scaling to Determine Market Channel Choice by Small Farmers in Indonesia. Association 2010 AAEA, CAES, & WAEA Joint Annual Meeting, Denver, Colorado, 25\u201327 July 2010"},{"key":"1100_CR20","unstructured":"IBM Corp. Released (2013) IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp http:\/\/www-01.ibm.com\/support\/docview.wss?uid=swg21476197"},{"issue":"5","key":"1100_CR21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","volume":"36","author":"HL Peay","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF (2014) A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther 36(5):624\u2013637","journal-title":"Clin Ther"},{"key":"1100_CR22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","volume":"256","author":"F Reed Johnson","year":"2009","unstructured":"Reed Johnson F, Van Houtven G, Ozdemir S et al (2009) Multiple sclerosis patients benefit-risk preferences serious adverse event risks versus treatment efficacy. J Neurol 256:554\u2013562","journal-title":"J Neurol"},{"key":"1100_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"K Beusterien","year":"2010","unstructured":"Beusterien K, Davies J, Leach M et al (2010) Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 8:50","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1100_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6605187","volume":"101","author":"K Beusterien","year":"2009","unstructured":"Beusterien K, Szabo S, Kotapati S et al (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 101(3):387\u2013389","journal-title":"Br J Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-015-1100-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1100-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T08:02:05Z","timestamp":1559376125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-015-1100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,7]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1007\/s11255-015-1100-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725960228.793511678","asserted-by":"object"}]},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,7]]}}}